Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29478502 | 1.00 | ROCK1 (0.51) | ROCK1SIGMAR1SMN1; SMN2OPRM1TP53 | |
| SCHEMBL618870 | 0.94 | OPRM1 (0.48) | ROCK1SIGMAR1SMN1; SMN2OPRM1TP53 | |
| SCHEMBL3905172 | 0.88 | ALDH1A1 (0.53) | ROCK1SIGMAR1SMN1; SMN2TP53MAPT | |
| SCHEMBL29542545 | 0.88 | ALDH1A1 (0.53) | ROCK1SIGMAR1SMN1; SMN2TP53MAPT | |
| SCHEMBL28159694 | 0.85 | MAPT (0.52) | ROCK1SIGMAR1SMN1; SMN2OPRM1TP53 | |
| SCHEMBL28160161 | 0.85 | ALDH1A1 (0.52) | ROCK1SIGMAR1SMN1; SMN2OPRM1TP53 | |
| SCHEMBL11601096 | 0.85 | SMN1; SMN2 (0.49) | ROCK1SIGMAR1SMN1; SMN2OPRM1TP53 | |
| SCHEMBL2201933 | 0.85 | SMN1; SMN2 (0.53) | ROCK1SIGMAR1SMN1; SMN2OPRM1TP53 | |
| SCHEMBL3145073 | 0.85 | ROCK1 (0.47) | ROCK1SIGMAR1SMN1; SMN2OPRM1TP53 | |
| SCHEMBL23632273 | 0.85 | ALDH1A1 (0.59) | SMN1; SMN2OPRM1TP53MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114774944-A | Electrochemical dehydrogenation method and system for organic hydrogen storage liquid | 云南电网有限责任公司电力科学研究院 | 2022-07-22 | — | — | CN | claimed |
| CN-112142663-B | Synthesis method of (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline | 中山奕安泰医药科技有限公司 | 2022-03-22 | — | — | CN | claimed |
| EP-2421823-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| WO-2010124086-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| JP-55122719-A | — | — | None | — | — | JP | disclosed |
| CN-114774944-A | Electrochemical dehydrogenation method and system for organic hydrogen storage liquid | 云南电网有限责任公司电力科学研究院 | 2022-07-22 | — | — | CN | disclosed |
| CN-112812060-B | Arylation method of tetrahydroquinoline | 绍兴文理学院 | 2022-04-29 | — | — | CN | disclosed |
| CN-112142663-B | Synthesis method of (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline | 中山奕安泰医药科技有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-112812060-A | Arylation method of tetrahydroquinoline | 绍兴文理学院 | 2021-05-18 | — | — | CN | disclosed |
| CN-110683986-B | Synthesis method of (S) 1-phenyl-1, 2,3, 4-tetrahydroisoquinoline | 中山奕安泰医药科技有限公司 | 2021-03-23 | — | — | CN | disclosed |
| CN-112142663-A | Synthesis method of (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline | 中山奕安泰医药科技有限公司 | 2020-12-29 | — | — | CN | disclosed |
| EP-3247771-B1 | PYRIDINES AND DERIVATIVES THEREOF AS COMPONENTS FOR USE IN OPTOELECTRONIC COMPONENTS | CYNORA GMBH (DE) | 2020-06-10 | — | — | EP | disclosed |
| WO-2016116522-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC COMPONENTS | CYNORA GMBH (DE) | 2016-07-28 | — | — | WO | disclosed |
| EP-3048156-A1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC COMPONENTS | cynora GmbH (DE) | 2016-07-27 | — | — | EP | disclosed |
| EP-3048155-A1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC COMPONENTS | cynora GmbH (DE) | 2016-07-27 | — | — | EP | disclosed |
| EP-2043639-A2 | PROCESSES FOR PREPARING POLYMORPHIC FORMS OF SOLIFENACIN SUCCINATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-04-08 | — | — | EP | disclosed |
| US-20080114028-A1 | Process for preparing polymorphic forms of solifenacin succinate | TEVA PHARMACEUTICALS USA, INC. | 2008-05-15 | — | — | US | disclosed |
| WO-2008013851-A2 | PROCESSES FOR PREPARING POLYMORPHIC FORMS OF SOLIFENACIN SUCCINATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-01-31 | — | — | WO | disclosed |
| EP-0401782-A2 | Titanyl phthalocyanine crystal, method of manufacture thereof and its use for electrophotographic photosensitive material | NEC CORPORATION (JP) | 1990-12-12 | — | — | EP | disclosed |
| JP-S55122719-A | MEDICINE COMPOSITION HAVING ANTIPYRETIC, ANALGESIC, AND ANTI-INFLAMMATORY ACTION | MOCHIDA PHARMACEUT CO LTD | 1980-09-20 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114028-A1 | Process for preparing polymorphic forms of solifenacin succinate | SUCNR1, UBE2V1, SUCLG2 | ROCK1 4841/4885SIGMAR1 1916/4885SMN1; SMN2 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.